Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ATR | Q13535 | 1/20 | 0.50 |
| ▸ | MAPK8 | P45983 | 1/20 | 0.45 |
| ▸ | MAPK9 | P45984 | 1/20 | 0.45 |
| ▸ | MAPK10 | P53779 | 1/20 | 0.45 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.39 |
| ▸ | METAP1 | P53582 | 1/20 | 0.39 |
| ▸ | CA1 | P00915 | 1/20 | 0.38 |
| ▸ | CA2 | P00918 | 1/20 | 0.38 |
| ▸ | PSMB8 | P28062 | 1/20 | 0.36 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.36 |
| ▸ | LCK | P06239 | 3/20 | 0.36 |
| ▸ | CYP17A1 | P05093 | 1/20 | 0.35 |
| ▸ | BRD9 | Q9H8M2 | 1/20 | 0.35 |
| ▸ | LMNA | P02545 | 1/20 | 0.35 |
| ▸ | TSHR | P16473 | 1/20 | 0.35 |
| ▸ | LEF1 | Q9UJU2 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5029628 | 0.86 | PTPN1 (0.56) | ATRPTPN1METAP1CA1CA2 | |
| SCHEMBL1066439 | 0.85 | METAP1 (0.45) | ATRMETAP1CA1CA2PSMB8 | |
| SCHEMBL3039310 | 0.79 | MAPT (0.49) | ATRMETAP1CA1CA2PSMB8 | |
| SCHEMBL1496857 | 0.79 | LCK (0.47) | ATRMAPK10PTPN1METAP1KDM4E | |
| SCHEMBL6220756 | 0.78 | MAPT (0.51) | MAPK8MAPK9MAPK10PTPN1CA1 | |
| SCHEMBL3960185 | 0.78 | ALDH1A1 (0.51) | MAPK8MAPK9MAPK10KDM4E | |
| SCHEMBL4765220 | 0.78 | MAPK8 (0.45) | MAPK8MAPK9MAPK10PTPN1KDM4E | |
| SCHEMBL23960291 | 0.78 | ATR (0.43) | ATRMETAP1CA1CA2PSMB8 | |
| SCHEMBL22774998 | 0.78 | CA1 (0.42) | ATRMETAP1CA1CA2PSMB8 | |
| SCHEMBL1483110 | 0.78 | CA1 (0.42) | ATRMETAP1CA1CA2PSMB8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3901151-B1 | HALOGENATED-HETEROARYL AND OTHER HETEROCYCLIC KINASE INHIBITORS, AND USES THEREOF | IOMX THERAPEUTICS AG (DE) | 2026-04-01 | — | — | EP | disclosed |
| US-20250296928-A1 | A SYNTHESIS SCHEME AND PROCEDURES FOR PREPARING A SIK3 INHIBITOR AND INTERMEDIATES THEREOF | IOMX THERAPEUTICS AG (DE) | 2025-09-25 | — | — | US | disclosed |
| CN-118369321-A | Synthetic schemes and procedures for preparing SIK3 inhibitors and intermediates thereof | 艾奥麦克斯治疗公司 | 2024-07-19 | — | — | CN | disclosed |
| WO-2024129956-A1 | THIENOAZEPINE IMMUNOCONJUGATES, AND USES THEREOF | BOLT BIOTHERAPEUTICS, INC. (US) | 2024-06-20 | — | — | WO | disclosed |
| US-20230348453-A1 | HALOGENATED-HETEROARYL AND OTHER HETEROCYCLIC KINASE INHIBITORS, AND USES THEREOF | IOMX THERAPEUTICS AG (DE) | 2023-11-02 | — | — | US | disclosed |
| US-20230348453-A1 | HALOGENATED-HETEROARYL AND OTHER HETEROCYCLIC KINASE INHIBITORS, AND USES THEREOF | IOMX THERAPEUTICS AG (DE) | 2023-11-02 | — | — | US | disclosed |
| WO-2023067021-A1 | A SYNTHESIS SCHEME AND PROCEDURES FOR PREPARING A SIK3 INHIBITOR AND INTERMEDIATES THEREOF | IOMX THERAPEUTICS AG (DE) | 2023-04-27 | — | — | WO | disclosed |
| WO-2023067021-A1 | A SYNTHESIS SCHEME AND PROCEDURES FOR PREPARING A SIK3 INHIBITOR AND INTERMEDIATES THEREOF | IOMX THERAPEUTICS AG (DE) | 2023-04-27 | — | — | WO | disclosed |
| EP-4139305-A1 | HALOGENATED-HETEROARYL AND OTHER HETEROCYCLIC KINASE INHIBITORS, AND USES THEREOF | iOmx Therapeutics AG (DE) | 2023-03-01 | — | — | EP | disclosed |
| CN-115667255-A | Halogenated heteroaryl and other heterocyclic kinase inhibitors and uses thereof | 艾欧麦克斯治疗股份公司 | 2023-01-31 | — | — | CN | disclosed |
| US-9809598-B2 | Heterocyclyl-butanamide derivatives | MERCK PATENT GMBH (DE) | 2017-11-07 | — | — | US | disclosed |
| US-20170073347-A1 | HETEROCYCLYL-BUTANAMIDE DERIVATIVES | MERCK PATENT GMBH (DE) | 2017-03-16 | — | — | US | disclosed |
| EP-3140295-A1 | HETEROCYCLYL-BUTANAMIDE DERIVATIVES | Merck Patent GmbH (DE) | 2017-03-15 | — | — | EP | disclosed |
| WO-2015169421-A1 | HETEROCYCLYL-BUTANAMIDE DERIVATIVES | MERCK PATENT GMBH (DE) | 2015-11-12 | — | — | WO | disclosed |
| US-8476278-B2 | Thiazole Derivatives as protein kinase inhibitors | MERCK SHARP & DOHME CORP. (US) | 2013-07-02 | — | — | US | disclosed |
| US-8476278-B2 | Thiazole Derivatives as protein kinase inhibitors | MERCK SHARP & DOHME CORP. (US) | 2013-07-02 | — | — | US | disclosed |
| US-20100331313-A1 | Thiazole Derivatives as Protein Kinase Inhibitors | SCHERING CORPORATION | 2010-12-30 | — | — | US | disclosed |
| CN-1117731-A | Heteroaromatic compounds with antipsychotic activity | WELLCOME FOUND (GB) | 1996-02-28 | — | — | CN | disclosed |
| EP-0683778-A1 | HETEROAROMATIC COMPOUNDS WITH ANTIPSYCHOTIC ACTIVITY | THE WELLCOME FOUNDATION LIMITED (GB) | 1995-11-29 | — | — | EP | disclosed |
| WO-1994018196-A1 | HETEROAROMATIC COMPOUNDS WITH ANTIPSYCHOTIC ACTIVITY | THE WELLCOME FOUNDATION LIMITED (GB) | 1994-08-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100331313-A1 | Thiazole Derivatives as Protein Kinase Inhibitors | DAPK2, DAPK1, JAK1 | ATR 617/4885MAPK8 158/4885MAPK9 129/4885 |
| US-20230348453-A1 | HALOGENATED-HETEROARYL AND OTHER HETEROCYCLIC KINASE INHIBITORS, AND USES THEREOF | ABL1, PRKDC, PRKACA | ATR 1763/4885MAPK8 287/4885MAPK9 421/4885 |
| US-20250296928-A1 | A SYNTHESIS SCHEME AND PROCEDURES FOR PREPARING A SIK3 INHIBITOR AND INTERMEDIATES THEREOF | SIK3, SIK1, SIK2 | ATR 615/4885MAPK8 611/4885MAPK9 201/4885 |
| US-20170073347-A1 | HETEROCYCLYL-BUTANAMIDE DERIVATIVES | TNKS, TANK, TBKBP1 | ATR 282/4885MAPK8 1410/4885MAPK9 1371/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.